Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus

Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.

    J&J's (JNJ) Erdafitinib Gets Breakthrough Therapy Status

    The breakthrough therapy designation for J&J's (JNJ) erdafitinib was based on efficacy findings from a phase II study, evaluating it in advanced urothelial cancer.

      Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

      Let's see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

        Merck's Keytruda Gets Priority Review for Cervical Cancer

        Merck's (MRK) sBLA for Keytruda to expand its label for the treatment of advanced cervical cancer gets acceptance for priority review by the FDA.

          Gilead Announces Positive Data on New HIV Therapy Biktarvy

          Gilead (GILD) announces encouraging data from a phase III study, on its new HIV therapy, Biktarvy, at the 2018 Conference on Retroviruses and Opportunistic Infections in Boston.

            Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss

            Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.

              5 Reasons Why Pfizer (PFE) Could be a Great Pick in 2018

              Pfizer's (PFE) outperformance is backed by decent quarterly results, positive news flow and regulatory updates.

                Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid

                Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.

                  The Zacks Analyst Blog Highlights: Home Depot, Glaxo, Marriott, DISH and O'Reilly

                  The Zacks Analyst Blog Highlights: Home Depot, Glaxo, Marriott, DISH and O'Reilly

                    Ionis Out-Licenses Second Candidate to AstraZeneca, Earns $30M

                    Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.

                      Swarup Gupta headshot

                      Foreign Stock Roundup: TOT, STO & GSK Earnings Impress, BP & SNY Disappoint

                      Global stocks were weighed down by massive losses and heightened volatility on Wall Street last week.

                        Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study

                        Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.

                          Glaxo (GSK) Earnings and Revenues Surpass Estimates in Q4

                          Glaxo's (GSK) Q4 earnings and revenues beat estimates. In the event of Advair generic introduction in the U.S. market by mid 2018, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

                            FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up

                            Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.

                              Glaxo (GSK) Stock Down Despite Q4 Earnings and Sales Beat

                              Glaxo's (GSK) Q4 earnings and revenue beat estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

                                Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18

                                Merck (MRK) beats estimates for earnings but misses the same for sales in Q4. Sales of Keytruda remain strong in the quarter.

                                  Is TransDigm (TDG) Poised for Another Earnings Beat in Q1?

                                  We expect TransDigm (TDG) to beat on first-quarter fiscal 2018 earnings, driven by bullish momentum in its proprietary engineered products business.

                                    Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?

                                    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might lead the company to an earnings beat in Q4.

                                      Will Tinder & PMC Growth Aid Match Group (MTCH) Q4 Earnings?

                                      Match Group's (MTCH) fourth-quarter 2017 earnings results to benefit from steady market traction of apps like Tinder, which are driving higher paid-member count.

                                        AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III

                                        AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.

                                          Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion

                                          The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.

                                            Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?

                                            J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.

                                              Inovio's Influenza Vaccine Shows Potential, Shares Rally

                                              Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.

                                                J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve

                                                J&J (JNJ) beat estimates for earnings while missing the same for sales in the fourth-quarter. It issued a mixed outlook for 2018.

                                                  Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?

                                                  J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.